Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study on Toripalimab Combined With Anlotinib and SBRT for Patients With Untreated Brain Metastases of Driven Gene-negative Non-small Cell Lung Cancer

NCT05021328 is registered in ClinicalTrials.gov with Hubei Cancer Hospital as lead sponsor.

NCT NCT05021328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05021328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study on Toripalimab Combined With Anlotinib and SBRT for Patients With Untreated Brain Metastases of Driven Gene-negative Non-small Cell Lung Cancer
Lead sponsor
Hubei Cancer Hospital
Phase
Phase 1
Overall status
Completed
Start date
October 1, 2021
Completion date
February 5, 2025
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc